Januvia Among 7 Product Adaptations Approved In Japan
This article was originally published in PharmAsia News
Japan announced the approval of additional adaptations for existing drugs on May 23, including Januvia tablets (sitagliptin phosphate hydrate) from MSD and Glactiv tablets (sitagliptin phosphate hydrate) from Shionogi for Type 2 diabetes treatment as were Takeda’s Nesina tablets (alogliptin benzoate).
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.